|
InterMune Stage: Venture Date of Investment: 2000 Web Site : http://www.intermune.com Stock Symbol : NASDAQ: ITMN |
 |
InterMune, Inc., based in Brisbane, CA, is an independent biopharmaceutical company focused on developing and commercializing innovative therapies in pulmonology and hepatology. The Company was founded in 1999 with a strategy of acquiring clinical-stage products that could benefit from increased development and commercial focus within targeted therapeutic areas. The Company’s pulmonology pipeline includes pirfenidone for idiopathic pulmonary fibrosis (IPF), a progressive disease characterized by inflammation and scarring of the lungs. In hepatology, InterMune, together with its partner Roche, is developing a protease inhibitor, danoprevir (also known as RG7227 and ITMN-191), for the treatment of hepatitis C. InterMune also sells Actimmune, an interferon-gamma approved for the treatment of two rare congenital disorders.
Warburg Pincus led InterMune's second round of private financing in 2000 to help fund product acquisitions and the execution of clinical trials for and commercialization of new product indications.
